How a Bike Rider’s Hallucinations Led to One of History’s Most Famous Antipsychotics!

In 1958, Belgian pharmacologist Paul Janssen identified R1625—a fluorinated butyrophenone—during systematic screening of compounds designed to counteract amphetamine effects. The substance demonstrated antipsychotic properties in animal models, leading to haloperidol’s European launch in 1959 under the brand name Haldol and its U.S. introduction in 1967.

From Racing Cyclists to Antipsychotic Therapy

Postwar professional cyclists frequently used amphetamines to enhance performance, and by approximately 1955, physician Fries Claes reported to Janssen that their toxic symptoms—including auditory hallucinations, delusions of persecution, thought disorders, and stereotyped behaviors—closely mirrored clinical features of paranoid schizophrenia. That observation was not unprecedented: as early as 1938, similar links had appeared in medical literature, and by 1953, London-based medical student P.H. Connell formally described “amphetamine psychosis” after observing such cases in emergency departments.

Janssen, who had recently established a research laboratory in Turnhout, Belgium, interpreted these parallels differently than prior clinicians. Rather than treating them as diagnostic warnings, he hypothesized that a compound blocking amphetamine’s physiological actions might also treat schizophrenia. He began with pethidine as a structural scaffold, synthesizing and testing numerous analogs. In 1958, after relocating his lab to Beerse, chemist Bert Hermans developed R1625, which inhibited amphetamine-induced agitation and stereotypy in animals while producing sedation and catalepsy comparable to chlorpromazine. Clinical trials followed at Liege Hospital and Paris’s St. Anne Hospital—the same institution instrumental in chlorpromazine’s development—confirming its efficacy.

Fluoxetine and the Rise of Rational Drug Design

Unlike haloperidol’s discovery, fluoxetine emerged from theory-driven methodology. By the mid-1960s, Swedish and Dutch researchers—including Arvid Carlsson, Margit Lindqvist, and Jacques Van Rossum—had identified dopamine as a neurotransmitter and proposed its hyperactivity in schizophrenia. Concurrently, American scientists Joseph J. Schildkraut and William E. Bunney advanced the monoamine hypothesis of depression, positing reduced serotonin, norepinephrine, and dopamine activity as central to the disorder.

Ray W. Fuller, an Illinois-born biochemist who joined Eli Lilly in the early 1960s, built on this framework. Drawing from his experience assisting at a mental hospital, he devised a predictive assay: administering chloroamphetamine to lower brain serotonin levels, then testing candidate compounds for their ability to restore those levels. He recruited Scottish organic chemist Brian B. Malloy, who selected diphenhydramine—an antihistamine whose structural lineage had previously yielded chlorpromazine and imipramine—as a starting point for molecular modification.

In 1971, the team assessed compounds using synaptosomal preparations from homogenized brain tissue. Their objective was to identify agents that selectively blocked serotonin reuptake—like imipramine—but with diminished impact on other neurotransmitters. Fluoxetine, identified in 1972 as the most potent compound meeting those criteria, entered human trials and was marketed by Lilly in January 1988 as Prozac. Within its first year, 2.5 million prescriptions were written in the United States; by 1993, that figure reached 4.5 million.

Divergent Pathways, Shared Impact

Haloperidol’s origin reflects creative intuition rooted in unexpected clinical observation—specifically, the behavioral consequences of amphetamine abuse among bicyclists. Fluoxetine, by contrast, exemplifies rational drug design: deliberate molecular alteration guided by a biochemical theory of illness. Subsequent antidepressants—including venlafaxine (serotonin–norepinephrine reuptake inhibition), bupropion (dopamine reuptake inhibition), and mirtazapine (selective receptor binding)—followed the same theoretical model. Though rational design yields more predictable outcomes, it rests upon foundational discoveries made by investigators who pursued the implications of anomalous phenomena—such as the psychosis-like states induced in intoxicated racers.